Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients with non-malignant diseases
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Treosulfan (Primary) ; Busulfan
- Indications Haemoglobinopathies; Immunodeficiency disorders; Inborn error metabolic disorders
- Focus Therapeutic Use
- Sponsors Medac
- 28 Oct 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 28 Oct 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2020.
- 09 Sep 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.